Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data

Juan W Valle, Ivan Borbath, Brad Rosbrook, Kathrine Fernandez, Eric Raymond

Research output: Contribution to journalArticlepeer-review


AIM: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors.

PATIENTS & METHODS: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5 mg on a continuous daily-dosing regimen) in two open-label extension studies.

RESULTS: Median (range) treatment exposure: 30.2 (0.7-269.4) and 87.1 (3.9-319.4) weeks for medium-term (n = 41) and long-term-treated (n = 61) populations, respectively. All patients experienced ≥1 adverse event (AE); 47 (45.6%) reported serious AEs. Common all-causality AEs: diarrhea (63.1%); neutropenia (43.7%); abdominal pain (40.8%). Fifteen (14.6%) patients discontinued treatment due to treatment-related AEs.

CONCLUSION: The safety of extended sunitinib treatment was consistent with the known safety profile of sunitinib in pancreatic neuroendocrine tumors.

Original languageEnglish
JournalFuture oncology (London, England)
Early online date31 Jan 2019
Publication statusPublished - 2019


  • long-term
  • pancreatic neuroendocrine tumor
  • safety
  • sunitinib

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data'. Together they form a unique fingerprint.

Cite this